ZVRA Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. (ZVRA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 77% planned / 23% discretionary
Largest single sale: $474.8K.
Where they traded
Last open-market purchase: September 12, 2025 — 1.0 years ago, by FAVORITO TAMARA A .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Thompson Rahsaan | Chief Legal & Compliance | Sell 10b5-1 | 42,666 | $11.13 | $474.8K | 37,569 −53.2% of holding | |
| Watton Corey Michael | Director | Sell | 12,300 | $11.25 | $138.4K | 1,800 −87.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.